PREVACID (lansoprazole) belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+ , K+ )-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. Lansoprazole does not exhibit anticholinergic or histamine type-2 antagonist activity.

PREVACID is a proton pump inhibitor (PPI). Refer to DOSAGE AND ADMINISTRATION table (below) for indications and usage.

See package insert for complete information.

Most commonly reported adverse reactions (≥1%): diarrhea, abdominal pain, nausea and constipation.

Contraindicated in patients with known severe hypersensitivity to any component of the PREVACID formulation.

• Symptomatic response with PREVACID does not preclude the presence of gastric malignancy. • PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea. • Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.